Abstract
Background/Objective: Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. The purpose of the present trial was to investigate its effect in preventing postoperative atrial fibrillation (POAF) after on-pump coronary artery bypass graft (CABG) surgery.
Methods: In the current prospective, randomized, (1 active: 2 control), single-blind (outcome assessors), single-centre clinical trial we recruited consecutive eligible patients scheduled for elective on-pump CABG. Participants were assigned to receive either oral ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge, or to receive usual care. Patients were monitored for the development of POAF.
Results: We enrolled 102 patients. Significantly lower incidence of POAF was noted in the ranolazine group compared with the control group (3 out of 34 patients, 8.8%, vs 21 out of 68 patients, 30.8%; p< 0.001). Mean values of left atrial diameter and left ventricular ejection fraction between the control and the ranolazine group were not significantly different.
Conclusion: Our findings suggest a protective role of oral ranolazine when administered in a moderate dose preoperatively in patients undergoing on-pump CABG surgery. Future studies based on a wider sample of patients will eventually support our conclusions.
Keywords: Ranolazine, atrial fibrillation, postoperative, coronary artery bypass graft surgery, prevention.
Current Vascular Pharmacology
Title:Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery
Volume: 11 Issue: 6
Author(s): Georgios I. Tagarakis, Isaac Aidonidis, Stella S. Daskalopoulou, Vassilios Simopoulos, Vassilios Liouras, Marios E. Daskalopoulos, Charalampos Parisis, Kiriaki Papageorgiou, Ioannis Skoularingis, Filippos Triposkiadis, Paschalis-Adam Molyvdas and Nikolaos B. Tsilimingas
Affiliation:
Keywords: Ranolazine, atrial fibrillation, postoperative, coronary artery bypass graft surgery, prevention.
Abstract: Background/Objective: Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. The purpose of the present trial was to investigate its effect in preventing postoperative atrial fibrillation (POAF) after on-pump coronary artery bypass graft (CABG) surgery.
Methods: In the current prospective, randomized, (1 active: 2 control), single-blind (outcome assessors), single-centre clinical trial we recruited consecutive eligible patients scheduled for elective on-pump CABG. Participants were assigned to receive either oral ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge, or to receive usual care. Patients were monitored for the development of POAF.
Results: We enrolled 102 patients. Significantly lower incidence of POAF was noted in the ranolazine group compared with the control group (3 out of 34 patients, 8.8%, vs 21 out of 68 patients, 30.8%; p< 0.001). Mean values of left atrial diameter and left ventricular ejection fraction between the control and the ranolazine group were not significantly different.
Conclusion: Our findings suggest a protective role of oral ranolazine when administered in a moderate dose preoperatively in patients undergoing on-pump CABG surgery. Future studies based on a wider sample of patients will eventually support our conclusions.
Export Options
About this article
Cite this article as:
Tagarakis I. Georgios, Aidonidis Isaac, Daskalopoulou S. Stella, Simopoulos Vassilios, Liouras Vassilios, Daskalopoulos E. Marios, Parisis Charalampos, Papageorgiou Kiriaki, Skoularingis Ioannis, Triposkiadis Filippos, Molyvdas Paschalis-Adam and Tsilimingas B. Nikolaos, Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/157016111106140128123506
DOI https://dx.doi.org/10.2174/157016111106140128123506 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Recent Developments in Cardiovascular Drug Therapy: Treatment of Atrial Arrhythmias with New Class III Drugs and beyond
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials Erythropoietin and Oxidative Stress
Current Neurovascular Research Neonatal Hypertension: An Underdiagnosed Condition, A Review Article
Current Hypertension Reviews Mesenchymal Stem Cells: A Good Candidate for Restenosis Therapy?
Current Vascular Pharmacology Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics Mechanisms of Intimal Hyperplasia Learned from a Murine Carotid Artery Ligation Model
Current Vascular Pharmacology Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis
Current Rheumatology Reviews Current Trends in the Surgical Armamentarium for Minimally Invasive Heart Valve Therapies
Recent Patents on Biomedical Engineering (Discontinued) Recent Patents in Imaging of the Vulnerable Atherosclerotic Plaque: The Search for the Holy Grail
Recent Patents on Medical Imaging Vascular Reactions of Iodinated X-Ray Contrast Media: Mechanisms and Possible Therapeutic Interventions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Update in Pharmacological Management of Coronary No-Reflow Phenomenon
Cardiovascular & Hematological Agents in Medicinal Chemistry Leukotrienes and Atherosclerosis
Current Drug Targets Pathogenesis of Neointima Formation Following Vascular Injury
Cardiovascular & Hematological Disorders-Drug Targets